Theodoros Foukakis

Publications
CV
Public outreach and news

Articles

Article: NATURE COMMUNICATIONS. 2024;15(1):3837
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
Wang K; Zerdes I; Johansson HJ; Sarhan D; Sun Y; Kanellis DC; Sifakis EG; Mezheyeuski A; Liu X; Loman N; Hedenfalk I; Bergh J; Bartek J; Hatschek T; Lehtio J; Matikas A; Foukakis T
Article: BREAST CANCER RESEARCH AND TREATMENT. 2024;204(2):299-308
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Zhu Y; Zerdes I; Matikas A; Cruz IR; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Wang K; Bergh JCS; Hatschek T; Foukakis T
Article: BREAST CANCER RESEARCH. 2024;26(1):38
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients
Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindstroem LS; Tobin NP
Article: BREAST CANCER RESEARCH. 2024;26(1):24
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Ronnlund C; Sifakis EG; Schagerholm C; Yang Q; Karlsson E; Chen X; Foukakis T; Weidler J; Bates M; Fredriksson I; Robertson S; Hartman J
Article: BREAST CANCER RESEARCH. 2024;26(1):4
Identification of a Notch transcriptomic signature for breast cancer
Braune E-B; Geist F; Tang X; Kalari K; Boughey J; Wang L; Leon-Ferre RA; D'Assoro AB; Ingle JN; Goetz MP; Kreis J; Wang K; Foukakis T; Seshire A; Wienke D; Lendahl U
Article: ECLINICALMEDICINE. 2024;67:102335
Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths - a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden
Rodriguez-Wallberg KA; Kieler H; Foukakis T; Li J; Gissler M; Oberg AS; Bergh J; Lundberg FE
Article: BMJ OPEN. 2023;13(12):e078023
ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study
Rodriguez-Wallberg KA; Nilsson HP; Bergh J; Malmros J; Ljungman P; Foukakis T; Stragliotto CL; Friman EI; Linderholm B; Valachis A; Andersson A; Harrysson S; Vennstrom L; Frisk P; Moerse H; Eloranta S
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(33):5118-5130
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Pfeiler G; Hlauschek D; Mayer EL; Deutschmann C; Kacerovsky-Strobl S; Martin M; Meisel JL; Zdenkowski N; Loibl S; Balic M; Park H; Prat A; Isaacs C; Bajetta E; Balko JM; Bellet-Ezquerra M; Bliss J; Burstein H; Cardoso F; Fohler H; Foukakis T; Gelmon KA; Goetz M; Haddad TC; Iwata H; Jassem J; Lee S-C; Linderholm B; Los M; Mamounas EP; Miller KD; Morris PG; Munzone E; Gal-Yam EN; Ring A; Shepherd L; Singer C; Thomssen C; Tseng L-M; Valagussa P; Winer EP; Wolff AC; Zoppoli G; Machacek-Link J; Schurmans C; Huang X; Gauthier E; Fesl C; Dueck AC; DeMichele A; Gnant M
Article: JOURNAL OF CLINICAL INVESTIGATION. 2023;133(22):e166666
FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters
Li M; Nishimura T; Takeuchi Y; Hongu T; Wang Y; Shiokawa D; Wang K; Hirose H; Sasahara A; Yano M; Ishikawa S; Inokuchi M; Ota T; Tanabe M; Tada K-I; Akiyama T; Cheng X; Liu C-C; Yamashita T; Sugano S; Uchida Y; Chiba T; Asahara H; Nakagawa M; Sato S; Miyagi Y; Shimamura T; Nagai LAE; Kanai A; Katoh M; Nomura S; Nakato R; Suzuki Y; Tojo A; Voon DC; Ogawa S; Okamoto K; Foukakis T; Gotoh N
Article: ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE. 2023;2023:1-4
Multiresolution Self-Supervised Feature Integration via Attention Multiple Instance Learning for Histopathology Analysis.
Tsiknakis N; Tzoras E; Zerdes I; Manikis GC; Acs B; Hartman J; Hatschek T; Foukakis T; Marias K
Article: CLINICAL CANCER RESEARCH. 2023;29(3):532-540
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Gryback P; Bjohle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023;120(1):e2209856120
Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction
Chen X; Sifakis EG; Robertson S; Neo SY; Jun S-H; Tong L; Min ATH; Lovrot J; Hellgren R; Margolin S; Bergh J; Foukakis T; Lagergren J; Lundqvist A; Ma R; Hartman J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2022;194(1):49-56
Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
Boman C; Kessler LE; Bergh J; Matikas A; Foukakis T
Article: MOLECULAR ONCOLOGY. 2022;16(12):2413-2431
Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer
Wang K; Li L; Franch-Exposito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Article: CANCERS. 2022;14(11):2615
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
Kjallquist U; Acs B; Margolin S; Karlsson E; Kessler LE; Hernandez SG; Ekholm M; Lundgren C; Olsson E; Lindman H; Foukakis T; Matikas A; Hartman J
Article: NPJ BREAST CANCER. 2021;7(1):144
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
Zerdes I; Simonetti M; Matikas A; Harbers L; Acs B; Boyaci C; Zhang N; Salgkamis D; Agartz S; Moreno-Ruiz P; Bai Y; Rimm DL; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Article: CANCERS. 2021;13(18):4655
Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Ruiz PM; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
Article: JAMA ONCOLOGY. 2021;7(9):1360-1367
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer A Phase 2 Randomized Clinical Trial
Hatschek T; Foukakis T; Bjohle J; Lekberg T; Fredholm H; Elinder E; Bosch A; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Azavedo E; Gryback P; Hellstrom M; Johansson H; Maes C; Zerdes I; Hartman J; Brandberg Y; Bergh J
Article: ESMO OPEN. 2021;6(4):100217
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)
Eriksson M; Reichardt P; Joensuu H; Krarup-Hansen A; Hagberg O; Hohenberger P; Hagberg H; Hansson L; Foukakis T; Pulkkanen K; Bauer S; Goplen D; Rossen PB; Hall KS
Article: CLINICAL NUTRITION. 2021;40(5):3370-3378
Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study
Wang K; Wu Q; Li Z; Reger MK; Xiong Y; Zhong G; Li Q; Zhang X; Li H; Foukakis T; Xiang T; Zhang J; Ren G
Article: ESMO OPEN. 2021;6(2):100076
bPrognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
Matikas A; Wang K; Lagoudaki E; Acs B; Zerdes I; Hartman J; Azavedo E; Bjohle J; Carlsson L; Einbeigi Z; Hedenfalk I; Hellstrom M; Lekberg T; Loman N; Saracco A; von Wachenfeldt A; Rotstein S; Bergqvist M; Bergh J; Hatschek T; Foukakis T
Article: NPJ BREAST CANCER. 2021;7(1):21
Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation
Wang K; Li Z; Chen X; Zhang J; Xiong Y; Zhong G; Shi Y; Li Q; Zhang X; Li H; Xiang T; Foukakis T; Radivoyevitch T; Ren G
Article: ESMO OPEN. 2020;5(6):e001032
PD-1 protein and gene expression as prognostic factors in early breast cancer
Matikas A; Zerdes I; Lovrot J; Sifakis E; Richard F; Sotiriou C; Rassidakis G; Bergh J; Valachis A; Foukakis T
Article: ACTA ONCOLOGICA. 2020;59(11):1382-1387
Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience
Kessler LE; Wiklander O; Hamberg E; Bergh J; Foukakis T; Matikas A
Article: JAMA ONCOLOGY. 2020;6(10):1581-1588
External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms
Salim M; Wahlin E; Dembrower K; Azavedo E; Foukakis T; Liu Y; Smith K; Eklund M; Strand F
Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(3):645-651
Chemotherapy use near the end-of-life in patients with metastatic breast cancer
Kessler LE; Sigfridsson J; Hatzidaki D; Bergh J; Foukakis T; Georgoulias V; Matikas A
Article: ANNALS OF ONCOLOGY. 2020;31(5):569-581
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Schmid P; Salgado R; Park YH; Munoz-Couselo E; Kim SB; Sohn J; Im S-A; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortes J; Loi S
Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(1):87-96
Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
Brandberg Y; Johansson H; Hellstrom M; Gnant M; Mobus V; Greil R; Foukakis T; Bergh J
Article: MOLECULAR ONCOLOGY. 2020;14(5):951-963
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease
Zerdes I; Sifakis EG; Matikas A; Chretien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2020;106(5):958-967
Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial
Bosma SCJ; Leij F; Vreeswijk S; de Maaker M; Wesseling J; van de Vijver M; Scholten A; Rivera S; Bourgier C; Auzac G; Foukakis T; Lekberg T; Bongard D; Loo C; Rutgers E; Bartelink H; Elkhuizen PHM
Article: CANCER. 2020;126(6):1175-1182
Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial
Papakonstantinou A; Matikas A; Bengtsson NO; Malmstrom P; Hedayati E; Steger G; Untch M; Hubbert L; Johansson H; Hellstrom M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;382(9):810-821
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid P; Cortes J; Pusztai L; McArthur H; Kuemmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J
Article: ACTA ONCOLOGICA. 2020;59(1):75-81
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer
Papakonstantinou A; Hedayati E; Hellstrom M; Johansson H; Gnant M; Steger G; Greil R; Untch M; Moebus V; Loibl S; Foukakis T; Bergh J; Matikas A
Article: NPJ BREAST CANCER. 2020;6:36
Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study.
Wang K; Sun J-Z; Wu Q-X; Li Z-Y; Li D-X; Xiong Y-F; Zhong G-C; Shi Y; Li Q; Zheng J; Shivappa N; Hébert JR; Foukakis T; Zhang X; Li H-Y; Xiang T-X; Ren G-S
Article: ONCOLOGIST. 2020;25(1):23-32
Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial
Mijwel S; Bolam KA; Gerrevall J; Foukakis T; Wengstrom Y; Rundqvist H
Article: CANCERS. 2019;11(10):E1479-1479
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Zerdes I; Wallerius M; Sifakis EG; Wallmann T; Betts S; Bartish M; Tsesmetzis N; Tobin NP; Coucoravas C; Bergh J; Rassidakis GZ; Rolny C; Foukakis T
Article: BRITISH JOURNAL OF CANCER. 2019;120(10):959-967
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Ribi K; Luo W; Colleoni M; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Di Lauro V; Gomez HL; Ruhstaller T; Abdi E; Biganzoli L; Mueller B; Barbeaux A; Graas M-P; Rabaglio M; Francis PA; Foukakis T; Pagani O; Graff C; Vorobiof D; Maibach R; Di Leo A; Gelber RD; Goldhirsch A; Coates AS; Regan MM; Bernhard J
Article: THE LANCET. 2019;393(10179):1440-1452
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials
Boddington C; Bradley R; Braybrooke J; Burrett J; Clarke M; Davies C; Davies L; Dodwell D; Duane F; Evans V; Gettins L; Godwin J; Gray R; Hills R; James S; Liu H; Liu Z; MacKinnon E; Mannu G; McGale P; McHugh T; Morris P; Pan H; Peto R; Read S; Taylor C; Wang Y; Wang Z; Bradley R; Braybrooke J; Gray R; Bergh J; Peto R; Gray R; Bradley R; Braybrooke J; Liu Z; Peto R; Davies L; Dodwell D; McGale P; Pan H; Taylor C; Barlow W; Bliss J; Bruzzi P; Cameron D; Fountzilas G; Loibl S; Mackey J; Martin M; Del Mastro L; Moebus V; Nekljudova V; De Placido S; Swain S; Untch M; Pritchard KI; Bergh J; Norton L; Fasching P; Harbeck N; Untch M; Piedbois P; Gnant M; Steger G; Di Leo A; Dolci S; Francis P; Larsimont D; Nogaret JM; Philippson C; Piccart-Gebhart MJ; Linn S; Peer P; Tjan-Heijnen V; Vliek S; Mackey J; Martin M; Slamon D; Bartlett JMS; Bramwell VH; Chen BE; Chia SKL; Gelmon K; Goss PE; Levine MN; Parulekar W; Pater JL; Pritchard KI; Rakovitch E; Shepherd LE; Tu D; Whelan T; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Weiss RB; Shan Y; Shao YF; Wang X; Xu B; Zhao DB; Bartelink H; Bijker N; Bogaerts J; Cardoso F; Cufer T; Julien JP; Poortmans PM; Rutgers E; van de Velde CJH; Carrasco E; Martin M; Segui MA; Blohmer JU; Costa SD; Gerber B; Jackisch C; Loibl S; Nekljudova V; von Minckwitz G; Bruzzi P; Giuliano M; De laurentiis M; De Placido S; Del Mastro L; Bamia C; Fountzilas G; Koliou G-A; Mavroudis D; A'Hern R; Bliss J; Cameron D; Ellis P; Kilburn L; Morden J; Yarnold JR; Sadoon M; Tulusan AH; Anderson S; Bass G; Costantino J; Dignam J; Fisher B; Geyer C; Mamounas EP; Paik S; Redmond C; Swain S; Wickerham L; Wolmark N; Del Mastro L; Venturini M; Bighin C; Bruzzi P; Del Mastro L; Pastorino S; Pronzato P; Sertoli MR; Barlow W; Bergh J; Foukakis T; Pritchard KI; Swain S; Cameron D; Albain K; Anderson S; Arriagada R; Barlow W; Bartlett J; Bergsten-Nordstrom E; Bliss J; Boccardo F; Bradley R; Brain E; Braybrooke J; Carey L; Clarke M; Coates A; Coleman R; Correa C; Costantino J; Cuzick J; Davidson N; Davies C; Davies L; Di Leo A; Dodwell D; Dowsett M; Duane F; Ewertz M; Forbes J; Francis P; Gelber R; Gnant M; Goldhirsch A; Goodwin P; Gray R; Hayes D; Hill C; Ingle J; Jagsi R; Janni W; Liu Z; Loibl S; MacKinnon E; Mannu G; Martin M; McGale P; Mukai H; Nekljudova V; Norton L; Ohashi Y; Paik S; Pan H; Peto R; Piccart M; Pierce L; Poortmans P; Raina V; Ravdin P; Rea D; Regan M; Robertson J; Rutgers E; Slamon D; Sparano J; Steger G; Taylor C; Tutt A; Viale G; Wang X; Whelan T; Wilcken N; Wolmark N; Wood W; Zambetti M
Article: BREAST CANCER RESEARCH. 2019;21(1):34
The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours
Lundberg A; Lindstroem LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Article: ANNALS OF ONCOLOGY. 2019;30(1):109-114
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
Matikas A; Foukakis T; Moebus V; Greil R; Bengtsson N-O; Steger GG; Untch M; Johansson H; Hellstrom M; Malmstrom P; Gnant M; Loibl S; Bergh J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2018;172(3):703-712
Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34years longitudinal data from the Stockholm-Gotland cancer registry
Falato C; Taylor SK; Szulkin R; Nordblom A; Eriksson L; Sofiadis A; Fredriksson I; Hartman J; Bergh J; Foukakis T
Article: ONCOIMMUNOLOGY. 2018;7(9):e1466017
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
Matikas A; Lovrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Hatschek T; Erlandsson A; Foukakis T
Article: CELL. 2018;173(4):879-893.e13
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Kim C; Gao R; Sei E; Brandt R; Hartman J; Hatschek T; Crosetto N; Foukakis T; Navin NE
Article: EJNMMI RESEARCH. 2018;8(1):25
Treatment response assessment with (R)-[¹¹CPAQ PET in the MMTV-PyMT mouse model of breast cancer
Tegnebratt T; Lu L; Eksborg S; Chireh A; Damberg P; Nikkhou-Aski S; Foukakis T; Rundqvist H; Holmin S; Kuiper RV; Samen E
Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488
Immune gene expression and response to chemotherapy in advanced breast cancer
Foukakis T; Lovrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Ferno M; Skoog L; Bergh J; Hatschek T
Article: CLINICAL CANCER RESEARCH. 2017;23(24):7512-7520
Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
Lundberg A; Lindstrom LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Article: CLINICAL CANCER RESEARCH. 2017;23(23):7225-7231
PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients
Tobin NP; Lundberg A; Lindstrom LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Ferno M; Czene K; Perou CM; Bergh J; Hatschek T
Article: CANCER CELL. 2017;32(5):669-683.e5
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon A; Tyrakis PA; Macias D; Velica P; Rundqvist H; Fitzpatrick S; Vojnovic N; Phan AT; Loman N; Hedenfalk I; Hatschek T; Lovrot J; Foukakis T; Goldrath AW; Bergh J; Johnson RS
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2017;114(45):E9635-E9644
Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production
Nakamura M; Zhang Y; Yang Y; Sonmez C; Zheng W; Huang G; Seki T; Iwamoto H; Ding B; Yin L; Foukakis T; Hatschek T; Li X; Hosaka K; Li J; Yu G; Wang X; Liu Y; Cao Y
Article: NATURE COMMUNICATIONS. 2017;8(1):228
Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer
Gao R; Kim C; Sei E; Foukakis T; Crosetto N; Chan L-K; Srinivasan M; Zhang H; Meric-Bernstam F; Navin N
Article: LAKARTIDNINGEN. 2017;114:EEIS
[Chemotherapy and targeted drugs to reinforce each other].
Foukakis T; Bergh J
Article: ONCOTARGET. 2016;7(46):74966-74978
Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes
Vardaki I; Ceder S; Rutishauser D; Baltatzis G; Foukakis T; Panaretakis T
Article: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA). 2016;316(18):1888-1896
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer A Randomized Clinical Trial
Foukakis T; von Minckwitz G; Bengtsson N-O; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellstrom M; Johansson H; Anderson H; Malmstrom P; Gnant M; Greil R; Mobus V; Bergh J
Article: CLINICAL CANCER RESEARCH. 2016;22(10):2417-2426
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Tobin NP; Wennmalm K; Lindstrom LS; Foukakis T; He L; Genove G; Ostman A; Landberg G; Betsholtz C; Bergh J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(14):1573-1579
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?
Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
Article: MOLECULAR ONCOLOGY. 2016;10(4):517-525
Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse
Falato C; Tobin NP; Lorent J; Lindstrom LS; Bergh J; Foukakis T
Article: MOLECULAR ONCOLOGY. 2015;9(7):1384-1391
Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer
Foukakis T; Lovrot J; Sandqvist P; Xie H; Lindstrom LS; Giorgetti C; Jacobsson H; Hedayati E; Bergh J
Article: ACTA ONCOLOGICA. 2015;54(4):522-529
A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden
Kessler L; Falato C; Margolin S; Bergh J; Foukakis T
Article: RADIOTHERAPY AND ONCOLOGY. 2015;114(3):322-327
First results of the preoperative accelerated partial breast irradiation (PAPBI) trial
van der Leij F; Bosma SCJ; van de Vijver MJ; Wesseling J; Vreeswijk S; Rivera S; Bourgier C; Garbay J-R; Foukakis T; Lekberg T; van den Bongard DHJGD; van Vliet-Vroegindeweij C; Bartelink H; Rutgers EJ; Elkhuizen PHM
Article: BREAST CANCER RESEARCH AND TREATMENT. 2014;147(2):407-414
Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer
Falato C; Lorent J; Tani E; Karlsson E; Wright PK; Bergh J; Foukakis T
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2014;74(3):549-558
Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide
von Stedingk H; Xie H; Hatschek T; Foukakis T; Ryden A; Bergh J; Rydberg P
Article: BRITISH JOURNAL OF CANCER. 2014;110(5):1378-1384
Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics
Colzani E; Johansson ALV; Liljegren A; Foukakis T; Clements M; Adolfsson J; Hall P; Czene K
Article: BMC CANCER. 2013;13:473
Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies
Milosevic J; Klinge J; Borg A-L; Foukakis T; Bergh J; Tobin NP
Article: JOURNAL OF SURGICAL ONCOLOGY. 2012;106(8):981-986
Anaplastic carcinoma of the thyroid gland: Treatment and outcome over 13 years at one institution
Segerhammar I; Larsson C; Nilsson I-L; Backdahl M; Hoog A; Wallin G; Foukakis T; Zedenius J
Article: ANNALS OF ONCOLOGY. 2012;23:x349-x353
When to order a biopsy to characterise a metastatic relapse in breast cancer
Foukakis T; Astrom G; Lindstrom L; Hatschek T; Bergh J
Article: EUROPEAN JOURNAL OF ENDOCRINOLOGY (EJE). 2012;166(4):657-667
Proteomic profiling of follicular and papillary thyroid tumors
Sofiadis A; Becker S; Hellman U; Hultin-Rosenberg L; Dinets A; Hulchiy M; Zedenius J; Wallin G; Foukakis T; Hoog A; Auer G; Lehtio J; Larsson C
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;130(2):553-560
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
Foukakis T; Fornander T; Lekberg T; Hellborg H; Adolfsson J; Bergh J
Article: THYROID. 2010;20(10):1067-1076
Proteomic Study of Thyroid Tumors Reveals Frequent Up-Regulation of the Ca²⁺-Binding Protein S100A6 in Papillary Thyroid Carcinoma
Sofiadis A; Dinets A; Orre LM; Branca RM; Juhlin CC; Foukakis T; Wallin G; Hoog A; Hulchiy M; Zedenius J; Larsson C; Lehtio J
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2009;35(2):369-374
Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy
Sofiadis A; Tani E; Foukakis T; Kjellman P; Skoog L; Hoog A; Wallin G; Zedenius J; Larsson C
Article: ENDOCRINE-RELATED CANCER. 2008;15(3):801-815
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma
Lee J-J; Au AYM; Foukakis T; Barbaro M; Kiss N; Clifton-Bligh R; Staaf J; Borg A; Delbridge L; Robinson BG; Wallin G; Hoog A; Larsson C
Article: JOURNAL OF PATHOLOGY. 2008;215(1):87-96
Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness
Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
Article: ENDOCRINE-RELATED CANCER. 2007;14(2):381-391
A PCR-based expression signature of malignancy in follicular thyroid tumors
Foukakis T; Gusnanto A; Au AYM; Hoog A; Lui W-O; Larsson C; Wallin G; Zedenius J
Article: THYROID. 2007;17(4):289-301
Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models
Lee J-J; Foukakis T; Hashemi J; Grimelius L; Heldin N-E; Wallin G; Rudduck C; Lui W-O; Hoog A; Larsson C
Article: ENDOCRINE-RELATED CANCER. 2007;14(1):125-134
The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma
Geli J; Kiss N; Lanner F; Foukakis T; Natalishvili N; Larsson O; Kogner P; Hoog A; Clark GJ; Ekstrom TJ; Backdahl M; Farnebo F; Larsson C
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM (JCEM). 2006;91(3):1143-1149
The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARγ fusion
Foukakis T; Au AYM; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui WO; Zedenius J; Larsson C
Article: TUMOR BIOLOGY. 2006;27(4):211-220
Molecular markers for discrimination of benign and malignant follicular thyroid tumors
Fryknas M; Wickenberg-Bolin U; Goransson H; Gustafsson MG; Foukakis T; Lee J-J; Landegren U; Hoog A; Larsson C; Grimelius L; Wallin G; Pettersson U; Isaksson A
Article: ONCOGENE. 2005;24(8):1467-1476
Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARγ fusion oncogene
Lui WO; Foukakis T; Lidén J; Thoppe SR; Dwight T; Höög A; Zedenius J; Wallin G; Reimers M; Larsson C
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2005;26(1):141-149
Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors
Foukakis T; Thoppe SR; Lagercrantz S; Dwight T; Weng WH; Svensson A; Höög A; Zedenius J; Wallin G; Lui WO; Larsson C
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM (JCEM). 2003;88(9):4440-4445
Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors
Dwight T; Thoppe SR; Foukakis T; Lui WO; Wallin G; Höög A; Frisk T; Larsson C; Zedenius J
Article: GENES CHROMOSOMES AND CANCER. 2002;35(1):74-80
Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer
Frisk T; Foukakis T; Dwight T; Lundberg J; Höög A; Wallin G; Eng C; Zedenius J; Larsson C
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1992;33(4):861-869
Gene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancer
Lee J-J; Geli J; Larsson C; Wallin G; Karimi M; Zedenius J; Hoog A; Foukakis T
Show more

All other publications

Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2023;192:104189
The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review
Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
Editorial comment: MOLECULAR ONCOLOGY. 2023;17(4):545-547
The interplay between eosinophils and T cells in breast cancer immunotherapy
Zerdes I; Matikas A; Foukakis T
Review: JOURNAL OF IMAGING. 2022;8(11):303
Harmonization Strategies in Multicenter MRI-Based Radiomics
Stamoulou E; Spanakis C; Manikis GC; Karanasiou G; Grigoriadis G; Foukakis T; Tsiknakis M; Fotiadis DI; Marias K
Review: CANCERS. 2022;14(8):1999
Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
Tzoras E; Zerdes I; Tsiknakis N; Manikis GC; Mezheyeuski A; Bergh J; Matikas A; Foukakis T
Review: FRONTIERS IN ONCOLOGY. 2022;12:999843
Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
Zhu Y; Tzoras E; Matikas A; Bergh J; Valachis A; Zerdes I; Foukakis T
Editorial comment: ANNALS OF ONCOLOGY. 2021;32(12):1457-1459
Adjuvant abemaciclib for high-risk breast cancer: the story continues
Spring L; Matikas A; Bardia A; Foukakis T
Review: ESMO OPEN. 2021;6(6):100289
The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis
Paakkola N-M; Karakatsanis A; Mauri D; Foukakis T; Valachis A
Corrigendum: JAMA ONCOLOGY. 2021;7(9):1405-1406
Errors in Abstract and Results.
Review: CANCER TREATMENT REVIEWS. 2021;99:102257
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
Boman C; Zerdes I; Martensson K; Bergh J; Foukakis T; Valachis A; Matikas A
Editorial comment: BREAST CARE. 2021;16(4):422-428
Expert Discussion: HER2-Positive Breast Cancer
Foukakis T; Matikas A; Oikonomidou O; Andreopoulou E; Mavroudis D
Editorial comment: ANNALS OF ONCOLOGY. 2021;32(2):129-132
SOLAR1s: alpelisib returns to earth?
Matikas A; Foukakis T
Corrigendum: BRITISH JOURNAL OF CANCER. 2020;122(7):1119
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Ribi K; Luo W; Colleoni M; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Di Lauro V; Gomez HL; Ruhstaller T; Abdi E; Biganzoli L; Müller B; Barbeaux A; Graas M-P; Rabaglio M; Francis PA; Foukakis T; Pagani O; Graiff C; Vorobiof D; Maibach R; Di Leo A; Gelber RD; Goldhirsch A; Coates AS; Regan MM; Bernhard J; SOLE Investigators
Review: CLINICAL CANCER RESEARCH. 2019;25(18):5717-5726
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
Review: ANNALS OF ONCOLOGY. 2019;30(7):1044-1050
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
Matikas A; Foukakis T; Swain S; Bergh J
Review: CANCERS. 2019;11(5):E628-628
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chretien S; Zerdes I; Bergh J; Matikas A; Foukakis T
Editorial comment: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):395-397
Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology
Matikas A; Foukakis T; Bergh J
Editorial comment: ANNALS OF ONCOLOGY. 2018;29(12):2278-2280
Carboplatin in the neoadjuvant treatment of triple-negative breast cancer-ready for prime time?
Foukakis T
Letter: JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(11):1280-1281
RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Matikas A; Foukakis T; Bergh J
Review: ONCOGENE. 2018;37(34):4639-4661
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Editorial comment: THE LANCET ONCOLOGY. 2018;19(7):850-852
Ribociclib in premenopausal women with advanced breast cancer
Foukakis T
Published conference paper: BREAST CANCER RESEARCH AND TREATMENT. 2018;168(2):349-355
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Matikas A; Margolin S; Hellstrom M; Johansson H; Bengtsson N-O; Karlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmstrom P; Villman K; Foukakis T; Bergh J
Review: ACTA ONCOLOGICA. 2017;56(9):1143-1151
Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts
Matikas A; Foukakis T; Bergh J
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2017;114:91-101
Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine
Matikas A; Foukakis T; Bergh J
Review: EXPERT REVIEW OF ANTICANCER THERAPY. 2017;17(4):319-326
Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
Matikas A; Foukakis T; Michalakis I; Georgoulias V
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(1):121-122
Estradiol Level and Menopause Reply
Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2016;374(14):1386-1387
A 21-Gene Expression Assay in Breast Cancer
Foukakis T; Falato C; Bergh J
Review: JOURNAL OF INTERNAL MEDICINE. 2015;278(6):545-570
The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer
Tobin NP; Foukakis T; De Petris L; Bergh J
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(1):84-85
Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors
Foukakis T; Lovrot J; Bergh J
Review: ACTA ONCOLOGICA. 2007;46(3):277-285
Advances in the treatment of patients with gastric adenocarcinoma
Foukakis T; Lundell L; Gubanski M; Lind PA
Thesis / dissertation: 2005
Basic and translational studies of follicular thyroid neoplasia
Foukakis, Theodoros
Show more

Employments

Senior Lecturer/Senior Physician, Department of Oncology-Pathology, Karolinska Institutet, 2020-

Degrees and Education

Docent, Karolinska Institutet, 2014
Doctor Of Philosophy, Department of Molecular Medicine and Surgery, Karolinska Institutet, 2005

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI